Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
NCT00854581 · University of Miami · PHASE4 · terminated · last registry update 2018-04-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Investigator Decision” | – | Registry record, University of Miami |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IFNAR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-04-12Results posted on the registry: Arrowhead Pharmaceuticals, ARC-520 + entecavir (NCT02577029)
- 2019-03-13Results posted on the registry: AstraZeneca, MEDI-546 + MEDI-546 (NCT01559090)
- 2019-03-12Phase 3 first posted: Biogen, Dimethyl Fumarate + Peginterferon Beta-1a (NCT03870763)
- 2019-02-26Results posted on the registry: AstraZeneca, Anifrolumab SC injection (300mg) + Anifrolumab IV infusion (300mg) (NCT02601625)
- 2019-02-07Phase 3 first posted: R-Pharm, Narlaprevir + Ritonavir (NCT03833362)
- 2019-01-22Results posted on the registry: Merck KGaA, Darmstadt, Germany, IFN beta 1a 44 mcg TIW + Curcumin (NCT01514370)
- 2019-01-15Results posted on the registry: AstraZeneca, Interferon beta-1a Nebuliser solution 48 μg/mL + Placebo (NCT02491684)
- 2018-11-01Also stopped (terminated): M.D. Anderson Cancer Center, PEG-Intron (NCT00037882)
- 2018-10-25Phase 3 first posted: Eiger BioPharmaceuticals, Lonafarnib + Ritonavir (NCT03719313)
- 2018-10-23Results posted on the registry: Hoffmann-La Roche, peginterferon alfa-2a [Pegasys] + ribavirin [Copegus] (NCT01429792)
- 2018-10-12Results posted on the registry: TaiGen Biotechnology Co., Ltd., TG-2349 + Ribavirin (NCT02340962)
- 2018-09-27Results posted on the registry: Getz Pharma, Peginterferon alfa-2a + Ribavirin (NCT02601976)
- 2018-09-20Results posted on the registry: Merck KGaA, Darmstadt, Germany, Rebif® + Rebif® (NCT02064816)
- 2018-09-19Results posted on the registry: Novartis Pharmaceuticals, Interferon beta-1a + Fingolimod (NCT01892722)
- 2018-08-27Also stopped (terminated): Merck Sharp & Dohme LLC, PEG-Intron™ + PEGASYS™ (NCT01641926)
- 2018-07-24Results posted on the registry: Ronald Hoffman, PEGASYS + Hydroxyurea (NCT01259856)
- 2018-07-24Results posted on the registry: Weill Medical College of Cornell University, Peginterferon alfa-2a (NCT01758588)
- 2018-07-24Also stopped (terminated): Weill Medical College of Cornell University, Peginterferon alfa-2a (NCT01758588)
- 2018-07-20Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Pegylated Interferon alpha-2b + Capecitabine (NCT02218164)
- 2018-07-03Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Entecavir and peginterferon (NCT01368497)
- 2018-07-03Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Entecavir and peginterferon (NCT01369199)
- 2018-06-27Results posted on the registry: EMD Serono, Rebif® + Copaxone® (NCT00078338)
- 2018-06-19Results posted on the registry: AbbVie (prior sponsor, Abbott), ABT-450/r + ABT-267 (NCT01609933)
- 2018-04-13Results posted on the registry: Hepatera Ltd., PEG IFN alfa-2a + Myrcludex B (NCT02637999)
- 2018-04-12Also stopped (withdrawn): MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute, interferon beta 1a + methotrexate (NCT00037115)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision